| Budget Amount *help |
¥118,950,000 (Direct Cost: ¥91,500,000、Indirect Cost: ¥27,450,000)
Fiscal Year 2016: ¥25,220,000 (Direct Cost: ¥19,400,000、Indirect Cost: ¥5,820,000)
Fiscal Year 2015: ¥22,750,000 (Direct Cost: ¥17,500,000、Indirect Cost: ¥5,250,000)
Fiscal Year 2014: ¥25,350,000 (Direct Cost: ¥19,500,000、Indirect Cost: ¥5,850,000)
Fiscal Year 2013: ¥20,540,000 (Direct Cost: ¥15,800,000、Indirect Cost: ¥4,740,000)
Fiscal Year 2012: ¥25,090,000 (Direct Cost: ¥19,300,000、Indirect Cost: ¥5,790,000)
|
|---|
| Outline of Final Research Achievements |
We have succeeded to establish the technology to construct human type artificial lymphoid tissues. We first established human lymphoid tissue stromal cells from human mesenchymal stem cells. The stromal cells were then cultured with recombinant human collagen peptides, which formed spheroids of the stromal cells. The spheroids and human peripheral blood lymphocytes were mixed and transplanted into renal subcapsular space of immunodeficient NSG mice. After 2-3 weeks, human lymph node-like tissues were formed at high efficiency. The tissues are composed of B cell follicles with FDC network, T cell areas containing FRC networks and dendritic cells. They contain fine networks of blood vessels with HEV, and lymph vessels. Antigen-specific antibody production and T cell responses were efficiently induced upon antigen stimulation.The structure of the tissues is stably maintained in NSG mice and easy to remove and transplant.
|
